{"id":434025,"date":"2026-05-09T23:05:11","date_gmt":"2026-05-09T23:05:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/434025\/"},"modified":"2026-05-09T23:05:11","modified_gmt":"2026-05-09T23:05:11","slug":"a-look-at-zymeworks-zyme-valuation-after-earnings-miss-and-key-fda-and-capital-return-updates","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/434025\/","title":{"rendered":"A Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return Updates"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

Earnings Miss Sets Up a More Complex Picture for Zymeworks <\/p>\n

Zymeworks (ZYME) just posted a wider quarterly loss and lower than expected revenue, while also highlighting upcoming FDA and pipeline milestones that could shape how you think about the stock over the next year.<\/p>\n

See our latest analysis for Zymeworks.<\/a><\/p>\n

The earnings miss helped drive a 1 day share price return of 3.66% decline and a 7 day share price return of 3.41% decline, yet the 90 day share price return of 17.08% and 1 year total shareholder return of very large suggest momentum has been building over a longer stretch.<\/p>\n

If this kind of earnings driven move has your attention, it could be a good moment to look at other biotech ideas powered by AI through the 35 healthcare AI stocks<\/a>.<\/p>\n

With shares up 17.08% over 90 days and a very large 1 year total return, yet still trading below some estimated value markers, the real question is whether Zymeworks is still mispriced or if the market is already accounting for future growth.<\/p>\n

Most Popular Narrative: 33.6% Undervalued <\/p>\n

The most followed narrative pegs Zymeworks’ fair value at $40.08 versus a last close of $26.60, framing the stock as materially discounted on that view.<\/p>\n

The analysts have a consensus price target of $40.08 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $31.0.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

Curious what has to happen for that gap to close? The narrative leans on fast improving earnings, richer margins, and a premium future profit multiple. The exact mix of growth, dilution and discount rate assumptions might surprise you.<\/p>\n

Result: Fair Value of $40.08 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, this depends on partners meeting clinical and regulatory milestones on schedule, and on early stage pipeline assets avoiding setbacks that could disrupt expected royalty streams.<\/p>\n

Find out about the key risks to this Zymeworks narrative.<\/a><\/p>\n

Next Steps <\/p>\n

With that optimism in mind, do not just rely on headlines or a single narrative; move quickly, review the details, and see what stands out in the 3 key rewards<\/a><\/p>\n

Ready to hunt for more opportunities? <\/p>\n

If Zymeworks is on your radar, do not stop there. Broaden your watchlist with other ideas that match your goals and risk comfort.<\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":247411,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,85,46,51249,56414,203593,203592],"class_list":["post-434025","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-il","tag-israel","tag-total-return","tag-total-shareholder-return","tag-zyme","tag-zymeworks"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/434025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=434025"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/434025\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/247411"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=434025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=434025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=434025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}